Capillary brain-derived p-tau217 for remote triaging of Alzheimer's disease pathology: Clinical performance in a CLIA/CAP-certified laboratory
- Journal
- Alzheimer's & dementia : the journal of the Alzheimer's Association (Q1)
- Published
- 1 November 2026
- Study design
- Cross-sectional study
- Evidence level
- Level 3, Low (CEBM 3b)
- Authors
- Elisabeth H Thijssen, Ansam Eghzawi, Federica Gibellini, Nicholas J Ashton, Inge M W Verberk, Salman Khwaja, et al.
- PMID
- 43046597
- DOI
- 10.1002/alz.72012
Why clinicians should know about it
- Picked for Biochemistry (medical) (paper of the day, 22 November 2026): Clinical validation of capillary p-tau217 assay and diagnostic performance
Abstract
INTRODUCTION: Expanding access to Alzheimer's disease (AD) blood biomarker testing through capillary collection beyond clinic-based venipuncture could enable earlier biological triage, specialist referral, and timelier initiation of disease-modifying therapies. Prior attempts to measure phosphorylated tau at amino acid 217 (p-tau217) in capillary blood have not achieved the diagnostic accuracy required for triaging. METHODS: This was a cross-sectional diagnostic validation study (January 2025-April 2026) across six US sites. Adults aged ≥ 50 years with cognitive concerns were recruited, including a community-based sample (N = 180) and specialty memory/research clinic sample with available amyloid positron emission tomography (PET; N = 64; total N = 244). Same-day paired capillary (Tasso upper-arm device) and venous samples were shipped ambient overnight and processed at a Clinical Laboratory Improvement Amendments (CLIA)/College of American Pathologists (CAP)-certified laboratory via proprietary capillary-to-assay workflow. Samples were measured using the BD-pTau217 singleplex assay on the NULISA platform. RESULTS: Among 244 participants (mean age 64.3 [standard deviation 11.9] years; 153 female [62.7%]; 51 Black [20.9%]), capillary and venous brain-derived p-tau217 (BD-p-tau217) correlated (R = 0.93, ρ = 0.73; both P < 0.001), with concentration-dependent bias on Bland-Altman analysis. In the PET-confirmed cohort (N = 64), capillary BD-p-tau217 yielded area under the curve (AUC) 0.959 (95.7% sensitivity, 83.3% specificity; positive predictive value [PPV] 93.6%, negative predictive value [NPV] 88.2%), meeting Global CEO Initiative on Alzheimer's Disease (CEOi) low-specificity and Alzheimer's Association guideline triage thresholds. Across the full cohort at 26% amyloid prevalence, against a composite reference standard, AUC was 0.959 (90.5% sensitivity, 89.0% specificity; PPV 74.0%, NPV 96.4%), meeting CEOi high-specificity triage thresholds. DISCUSSION: Capillary BD-p-tau217 met clinical performance standards for remote AD triage, to our knowledge the first capillary p-tau217 test to meet these standards, suggesting it may support triage of patients for further diagnostic evaluation, including specialist referral and confirmatory testing.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.